Wednesday, November 20, 2024
Lawyers Run The WorldFTC Issues Dietary Supplement Marketing Guidance

FTC Issues Dietary Supplement Marketing Guidance

-

- Advertisment -spot_img

Earlier this week, in cooperation with the Food and Drug Administration, the Federal Trade Commission circulated a consumer-focused reminder regarding dietary supplements.

“Dietary supplements may seem like harmless health boosters. But while some have proven benefits, many don’t. Unlike drugs, dietary supplements aren’t evaluated or reviewed by FDA for safety and effectiveness, and even “natural” supplements can be risky depending on the medicines you take or the medical conditions you have. In recent years, hundreds of supplements also have been found to be tainted with drugs and other chemicals. Always talk to your doctor before you take a new supplement, and avoid any supplement claiming it’s a “cure.”

Dietary supplements include vitamins and minerals, amino acids, enzymes, herbs, animal extracts and probiotics. They can take numerous forms (e.g., capsules, liquids and powders). However, dietary supplements are not “drugs,” and do not undergo FDA review for safety and effectiveness prior to sale.

The Commission cautions that dietary supplements may not always be safe or harmless. In fact, even “natural” supplements can be risky for those that are taking certain medications or that possess certain medication conditions. According to the Commission, some supplements have been found to be tainted with drugs or other chemicals.

The FDA has discovered hundreds of “dietary supplements” containing drugs or other chemicals, particularly in products for weight loss, sexual enhancement or bodybuilding. The “extra ingredients” are not typically listed on the label but could potentially result in serious side effects or interact in dangerous ways with medicines or other supplements being taken.

Tainted supplements often are sold with deceptive claims, such as “100% natural” and “safe.”

Marketers should avoid misleading trigger terms and related claims, such as alternatives to FDA-approved drugs, effects similar to prescription drugs, legal alternatives to anabolic steroids, and rapid effects or results.

Even “traditional remedies” with a long history of use are not guaranteed to be safe in all cases.

Substances for which safety concerns have been raised include comfrey, chaparral, lobelia, germander, aristolochia, ephedra (ma huang), L-tryptophan, germanium, magnolia-stephania and stimulant laxative ingredients (like those found in dieter’s teas).

According to the Commission, comfrey, for example, contains certain alkaloids that can cause serious liver damage, and aristolochia can cause kidney failure.

Additionally, certain vitamins and minerals, when taken in inappropriate amounts, can potentially cause problems. For example, according to the National Academy of Sciences, too much vitamin A can reduce bone mineral density, cause birth defects, and lead to liver damage.

Promises for a quick cure or solution for a serious health problem will always draw the FTC’s ire. Pursuant to federal law, dietary supplements cannot be promoted for the treatment of a disease because they are not proven to be safe and effective.

Increased regulatory attention will also result from claims that a product cures a wide variety of health problems, suggestions a product can treat or cure diseases, words like scientific breakthrough or secret ingredient, misleading use of scientific-sounding terms, undocumented testimonials by patients or doctors claiming miraculous results, and representations of limited availability and a need to pay in advance.

Lastly, dietary supplements often include claims about the effect of a substance on maintaining the body’s normal structure or function (e.g., “Product X promotes healthy joints and bones”). Such claims must include the disclaimer: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease.”

Contact an experienced FTC defense lawyer to discuss dietary supplement marketing compliance considerations for affiliate advertisers.

Follow the author on Twitter, here.

ADVERTISING MATERIAL. These materials are provided for informational purposes only and are not to be considered legal advice, nor do they create a lawyer-client relationship. No person should act or rely on any information in this article without seeking the advice of an attorney. Information on previous case results does not guarantee a similar future result. Hinch Newman LLP | 40 Wall St., 35thFloor, New York, NY 10005 | (212) 756-8777.

Richard B. Newman
Richard B. Newmanhttp://www.hinchnewman.com
Richard B. Newman is an Internet Lawyer at Hinch Newman LLP focusing on advertising law, Internet marketing compliance, regulatory defense and digital media matters. His practice involves conducting legal compliance reviews of advertising campaigns across all media channels, regularly representing clients in high-profile investigative proceedings and enforcement actions brought by the Federal Trade Commission and state attorneys general throughout the country, advertising and marketing litigation, advising on email and telemarketing best practice protocol implementation, counseling on eCommerce guidelines and promotional marketing programs, and negotiating and drafting legal agreements.

What's your opinion?

Latest news

The AdTech Wizard of Odds: Gareth Holmes on Streaming Ads, Helicopters, and Unleashing Sweden’s Secret Sauce 

Adtech is often described as a wild west, but Gareth Holmes makes it sound more like Cirque du Soleil—complete...

Zeta Global: AI Hype, Data Breaches, and Damage Control

Zeta Global (NYSE: ZETA), the self-proclaimed “AI-Powered Marketing Cloud,” has been spinning like a politician in a scandal. Accusations...

Catalina Salazar: The #martech Dynamo Turning Wolt Into a Retail Media Juggernaut

If retail media were a chess game, Catalina Salazar would be the queen—commanding the board, making bold moves, and...

AdMonsters Publishers Forum: Publishers’ Group Therapy, With Coffee and Cookie Anxiety

The AdMonsters Publishers Forum has officially kicked off, and it’s already a whirlwind of grievances, guarded optimism, and, of...

Streamlined or Screwed? The Real Cost of Curation for Publishers

It’s official: ad tech has found its new favorite shiny object. Say hello to curation, a word you can’t escape...

Can Innovid Turn Its Adtech Aspirations Into Actual Profits, or Is It Just Playing in the Sandbox?

Innovid Corp. is stuck in adtech purgatory—a company brimming with potential but weighed down by enough challenges to keep...

Must read

Zeta Global: AI Hype, Data Breaches, and Damage Control

Zeta Global (NYSE: ZETA), the self-proclaimed “AI-Powered Marketing Cloud,”...

Catalina Salazar: The #martech Dynamo Turning Wolt Into a Retail Media Juggernaut

If retail media were a chess game, Catalina Salazar...

You might also likeRELATED
Recommended to you